When a company as established as CSL Ltd (ASX: CSL) loses around $45 billion in market value, it's worth stopping to ask a simple question. Has the long-term investment case really deteriorated that much, or has sentiment run well ahead of reality?
At around $183.81 a share, CSL shares are trading a long way below their 52-week high of $282.20. Its market capitalisation has fallen from roughly $135 billion at its peak to closer to $90 billion today. That is a massive reset for one of the ASX's highest-quality healthcare businesses.
I think the market has gone too far.
Image source: Getty Images
Why has sentiment turned so negative
There's no denying that CSL has had a difficult period, and the share price weakness didn't come out of nowhere.
The biggest source of frustration has been CSL Behring, the plasma therapies division that underpins the long-term growth story. Margin recovery has been slower than expected as the business works through higher collection costs and post-pandemic inefficiencies.
At the same time, the Seqirus vaccines business has been impacted by weaker-than-expected influenza vaccination rates in the US, forcing management to lower near-term expectations.
China has also weighed on results. Softer demand for albumin products has pressured volumes and added another headwind during a period when investor patience was already thin.
The CSL112 setback that still hangs over sentiment
One issue that is sometimes forgotten but remains important is the failed CSL112 program in 2024.
CSL112 was being evaluated in the Phase 3 AEGIS-II trial for its ability to reduce major adverse cardiovascular events following an acute myocardial infarction. While the drug showed no major safety or tolerability concerns, it did not meet its primary efficacy endpoint.
As a result, CSL confirmed there are no plans for a near-term regulatory filing. This was a significant blow, given that analysts had previously estimated peak sales potential of up to US$3 billion per year. Even though this outcome is now well understood, it continues to weigh on investor confidence in CSL's pipeline.
Why I think CSL shares have been sold off too far
While these challenges explain why sentiment is poor, I don't think they justify the scale of value destruction.
CSL remains one of only three global tier-one plasma companies, operating in an oligopolistic market with extremely high barriers to entry. Its control of plasma collection capacity, the key constraint in the system, has not changed.
Many of the current headwinds are cyclical or transitional rather than structural. Influenza vaccination rates can recover. Albumin demand in China can normalise. Plasma margins can improve as efficiency initiatives take hold.
Even the CSL112 failure, while disappointing, does not undermine CSL's broader research and development capability. Drug development carries inherent risk, and CSL has a long track record of disciplined, commercially focused R&D.
Foolish Takeaway
At today's share price, expectations are far lower than they were a few years ago. The market no longer assumes rapid margin recovery or flawless execution, which I think creates a more balanced risk-reward profile.
I'm not expecting a quick return to previous highs. But when a world-class healthcare business loses around $50 billion in value while its core competitive advantages remain intact, it suggests to me that the market has become overly pessimistic.
That's why I think the market is wrong about CSL shares.
